Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Aberdeen Group plc

Key Points

• Aberdeen Group plc reduced its stake in Zimmer Biomet Holdings, Inc. by 57.6%, selling 213,381 shares and retaining 156,902 shares worth approximately $17.6 million.
• Several institutional investors recently acquired new stakes in Zimmer Biomet, indicating strong institutional interest, with institutional and hedge funds owning about 88.89% of the company's stock.
• ZBH recently announced a quarterly dividend of $0.24 per share, reflecting an annualized payout of $0.96 and a dividend yield of 0.9%.

Aberdeen Group plc decreased its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 57.6% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 156,902 shares of the medical equipment provider's stock after selling 213,381 shares during the period. Aberdeen Group plc owned about 0.08% of Zimmer Biomet worth $17,618,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Zimmer Biomet by 0.7% during the first quarter. Vanguard Group Inc. now owns 23,052,925 shares of the medical equipment provider's stock valued at $2,609,130,000 after buying an additional 166,763 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Zimmer Biomet by 1.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,760,444 shares of the medical equipment provider's stock worth $1,559,147,000 after purchasing an additional 176,337 shares during the last quarter. Northern Trust Corp increased its position in shares of Zimmer Biomet by 7.6% during the fourth quarter. Northern Trust Corp now owns 2,370,224 shares of the medical equipment provider's stock worth $250,367,000 after purchasing an additional 167,435 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Zimmer Biomet by 251.3% during the 1st quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider's stock valued at $235,571,000 after purchasing an additional 1,488,918 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Zimmer Biomet by 2.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,058,898 shares of the medical equipment provider's stock worth $233,009,000 after buying an additional 58,060 shares during the last quarter. Institutional investors own 88.89% of the company's stock.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock traded up $3.2070 on Friday, hitting $107.6270. 1,099,322 shares of the company were exchanged, compared to its average volume of 2,055,610. The company has a 50-day moving average price of $95.19 and a 200 day moving average price of $99.32. The stock has a market capitalization of $21.32 billion, a price-to-earnings ratio of 26.19, a price-to-earnings-growth ratio of 2.08 and a beta of 0.68. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $116.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The business had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. During the same period last year, the company earned $2.01 EPS. The company's revenue for the quarter was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th were paid a dividend of $0.24 per share. The ex-dividend date of this dividend was Thursday, June 26th. This represents a $0.96 annualized dividend and a yield of 0.9%. Zimmer Biomet's dividend payout ratio (DPR) is 23.36%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Truist Financial set a $101.00 price target on Zimmer Biomet in a research note on Tuesday, May 6th. Robert W. Baird lowered their price target on Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. JMP Securities decreased their target price on Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating for the company in a report on Wednesday, May 7th. Royal Bank Of Canada upped their price objective on shares of Zimmer Biomet from $112.00 to $115.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Finally, UBS Group raised their target price on shares of Zimmer Biomet from $91.00 to $96.00 and gave the stock a "sell" rating in a report on Friday, August 8th. Nine research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $111.44.

Insider Buying and Selling

In other news, insider Sang Yi sold 1,000 shares of the stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total transaction of $95,000.00. Following the completion of the transaction, the insider directly owned 20,424 shares in the company, valued at approximately $1,940,280. This represents a 4.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.39% of the stock is owned by corporate insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.